Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome

Table 4 Adjusted hazards for ACS re-hospitalization by clopidogrel duration (9, 12, 15 months); DES subgroup

DES-subgroup analysis	Unadjusted hazard ratio	p*	Adjusted hazard ratio	p*
DES-subgroup analysis	HR (95% CI)	p*	HR (95% CI)	p*
Clopidogrel use for ≥ 9 mo	0.71 (0.47-1.07)	0.10	0.68 (0.44-1.06) ^*	0.09
Clopidogrel use for ≥ 12 mo	0.58 (0.35-0.98)	0.04	0.52 (0.29-0.92) †	0.02
Clopidogrel use for ≥ 15 mo	0.91 (0.46-1.82)	0.79	0.76 (0.37-1.56) ‡	0.45

^*Adjusted for comorbidities (hypertension, DM uncontrolled, myocardial infarction), use of aspirin, NSAID, multivessel PCI, number of stents, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
† Adjusted for comorbidities (hypertension, DM uncontrolled, GI bleeding/ulcer, myocardial infarction), use of aspirin, NSAID, cholesterol, multivessel PCI, number of stents, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
‡ Adjusted for comorbidities (hypertension, DM uncontrolled, GI bleeding/ulcer, myocardial infarction), use of NSAID, multivessel PCI, number of stents, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.

ISSN: 1471-2261